Introduction
============

Choroideremia (CHM, OMIM: 303100) is a rare X-linked recessive inherited disorder that causes chorioretinal dystrophy with typical clinical features such as progressive degeneration of the choriocapillaris, retinal pigment epithelium (RPE), and photoreceptors.[@b1-tacg-11-001] Its prevalence ranges from 1:50,000 to 1:100,000.[@b2-tacg-11-001] Male patients develop night blindness in their childhood and gradually progress to loss of peripheral vision, and finally, some of them will reach complete peripheral blindness at their middle age with only tunnel vision left behind. Female carriers are usually asymptomatic, as to the heterozygous gene, some of them occasionally show mild symptoms as they reach middle age.[@b3-tacg-11-001],[@b4-tacg-11-001] Thus, with the progression of the disease, central vision is typically maintained in men as the fovea is spared.

CHM is caused by mutations in the *CHM* gene, which is mapped on chromosome Xq21.2-21.3 in 186,382 bp.[@b5-tacg-11-001] *CHM* mRNA comprises 15 exons, and it is expressed in many types of tissues including choroid, retinal photoreceptor, RPE, and lymphocyte tissues.[@b6-tacg-11-001] Ran et al reported that there are more than 100 different pathogenic *CHM* variants in the RetinoGenetics.[@b7-tacg-11-001] These variants demonstrate deletions, translocations, missense mutations, nonsense mutations, and splice-site mutations[@b6-tacg-11-001],[@b8-tacg-11-001],[@b9-tacg-11-001] and have been identified in the 15-exon gene. The *CHM* gene encodes for Rab escort protein-1 (REP1) which comprises 653 amino acids.[@b10-tacg-11-001] REP1 plays a significant role in the intracellular vesicular trafficking process as well as in the post-translational isoprenyl modification of Rab proteins.[@b11-tacg-11-001],[@b12-tacg-11-001]

Nowadays, varieties of molecular techniques have been invented to detect genetic mutations, for example, Sanger sequencing, but this technique cannot rapidly screen large numbers of mutations in samples. Fortunately, this problem can be solved by massive next-generation sequencing (NGS),[@b13-tacg-11-001] but both Sanger sequencing and NGS are expensive. The amplification refractory mutation system (ARMS), also termed allele-specific PCR, is a very simple method for detecting any known mutations involving single base changes or small deletions, which is based on the use of sequence-specific PCR primers that allow amplification of test DNA only when the target allele is contained within the sample. ARMS technique demands only PCR amplification and gel electrophoresis of the amplicons.

In ARMS technique, one PCR comprises one allele-specific oligonucleotide primer at 5′-end and a common primer at 3′-end. If the presence of an amplified mutant is detected by agarose gel electrophoresis, it suggests that the target sequence contains the mutant allele. Similarly, if the result displays an absence of the amplified mutant, it indicates the presence of the normal DNA sequence on that specific point.

In the same way, a normal primer at 5′-end together with a common primer at 3′-end was used in another PCR. If normal amplified product is present, it reveals the existence of a natural DNA sequence, whereas if normal amplified product is absent, then it reveals the presence of a mutant allele.[@b14-tacg-11-001]--[@b16-tacg-11-001] If there are both normal and mutant amplified products, then it reveals heterozygous gene variant by the existence of both normal DNA sequence and mutant DNA sequence within an individual.

In this study, evaluation of the ARMS technique for prenatal gene diagnosis of CHM with *CHM* gene point mutation was performed. This is a cheap, fast, accurate, and reliable pre- and postnatal diagnostic technique which provides the possibility to use it in the identification of various X-linked recessive gene mutations in western China and other undeveloped or developing countries.

Materials and methods
=====================

Clinical diagnosis and sample collection
----------------------------------------

A Chinese proband with CHM was diagnosed previously ([Figure 1A](#f1-tacg-11-001){ref-type="fig"}).[@b17-tacg-11-001] DNA templates from the proband and his family of peripheral leukocytes and from the amniotic fluid of fetus at 17 weeks of pregnancy, were isolated using a previously described method.[@b18-tacg-11-001],[@b19-tacg-11-001] The quality of DNA was measured by a NanoDrop-2000-spectrophotometer. High quality intact genomic DNA with an optical density ratio of 260/280\~1.8 and 260/230\>1.5 were used for further analysis. The study was approved by the ethical committee of Southwest Medical University according to the Helsinki Declaration (1983 Revision). Pregnant women signed informed consent forms for approval of the prenatal diagnosis.

Design of ARMS' primers
-----------------------

We designed the 5′ ARMS' primers with wild and mutant types with or without one base mismatched at the 3′-end following the nonsense mutation (c.C799T:p.R267X) of the *CHM* gene, respectively.[@b5-tacg-11-001] In addition, a common primer located at the 3′ terminus of *CHM* gene was designed. [Table 1](#t1-tacg-11-001){ref-type="table"} presents the information of primers.

ARMS-PCR amplification
----------------------

PCR was performed in a 10 µL reaction volume for DNA samples M001, M002, M003, M004, M050, and M051 that comprised 1 µL DNA template (15 ng), 1 µL 3.3 µM primers, 5 µL 2X PCR Taq Master Mix (TianGen Biotech Co. Ltd., Beijing, People's Republic of China), and 3 µL double-distilled water. PCR cycles were performed in a programmable thermal cycler (Applied Biosystems Veriti^®^ 96-Well Thermal Cycler, Life Technologies, Foster City, CA, USA).[@b20-tacg-11-001] PCR regimen was as follows: initial denaturation at 95°C for 60 s, followed by 33 cycles for 30 s at 94°C, 30 s at 61°C, 40 s at 72°C, and then a final extension for 5 min at 72°C, and finally the PCR products were maintained at 4°C in the end. In case of M151, which was amniotic fluid DNA sample with a lower concentration, we increased the total cycles to 35, and the rest of the conditions were same as the others.

Agarose gel electrophoresis
---------------------------

PCR products were resolved on a 1% agarose gel with 1× Tris--acetate-ethylenediaminetetraacetic acid (TAE) buffer, and then subjected to electrophoresis at 120 V for 30 min. The agarose gel was stained with 0.5 µg/mL ethidium bromide and photographed by ChemiDocXR (Bio-Rad, Hercules, CA, USA).[@b19-tacg-11-001],[@b20-tacg-11-001] DNA Marker (DL2000) for electrophoresis was purchased from TaKaRa Biotechnology Co. Ltd., (Dalian, People's Republic of China).

Mutation validation
-------------------

To validate the ARMS-PCR results, the variant was sequenced by Sanger method on an ABI 3500 DX Genetic Analyzer (ABI, Thermo Fisher Scientific, Waltham, MA, USA) with primer CHM-R by amplification using the primer pair CHM-L and CHM-R (length of the product is 637 bp) ([Table 2](#t2-tacg-11-001){ref-type="table"}).

Results
=======

Designing of ARMS amplification primers
---------------------------------------

In this study, we recruited a Chinese pedigree with CHM to perform the analysis using ARMS technique([Figure 1A](#f1-tacg-11-001){ref-type="fig"}). The results by Sanger sequencing with a variant (c.C799T:p. R267X) in the exon 6 of the *CHM* gene (GenBank accession number: NM_000390) on the X chromosome in the proband (I:1) and his son (II:3) with normal phenotype are shown in [Figure 1B and C](#f1-tacg-11-001){ref-type="fig"}, respectively. As seen in [Figure 1](#f1-tacg-11-001){ref-type="fig"}, I:1 (M001) is the proband of pedigree (indicated by an arrow) with *CHM* gene nonsense mutation from C→T ([Figure 1B](#f1-tacg-11-001){ref-type="fig"}), whereas proband's son (II:3) was normal both in phenotype and genotype with no mutation ([Figure 1C](#f1-tacg-11-001){ref-type="fig"}). His daughter was a carrier with an unborn fetus which was tested for inheritance of the mutant gene from the mother.

In order to establish and optimize the ARMS condition, two wild-type primer sets were designed: wild-type primer (CHM-WT) and point mutation wild-type primer (CHM-WT2) which matched with wild-type sequence of *CHM*, sharing the 3′ common primer (CHM-C3) as primer pairs (WT+C) and (WT2+C); two mutant primer sets were designed: mutant-type primer (CHM-MT) and point mutation for mutant-type primer (CHM-MT2) which matched with mutant-type sequence of *CHM* c.C799T, sharing the 3′ common primer (CHM-C3) as primer pairs (MT+C) and (MT2+C) ([Table 1](#t1-tacg-11-001){ref-type="table"}). The length of the PCR product was 490 bp. The artificial mismatch at the 3rd position of 3′-end in both CHM-WT2 and CHM-MT2 were designed to enhance PCR amplification.

The combination of primer pair (MT+C), which matched with the mutant *CHM* gene c.C799T, was used to detect the mutant, and the combination of primer pair (MT2+C) with one base mismatch was used to enhance the specificity for detecting the mutant *CHM* gene c.C799T.

Optimization of ARMS amplification
----------------------------------

PCR amplification was performed to optimize ARMS condition by the aforementioned four primer pairs using DNA templates M001 (I:1) and M002 (II:3). As seen in [Figure 2](#f2-tacg-11-001){ref-type="fig"}, all four primer pairs amplified specific bands with right size, except the primer pair (WT+C), with no mismatch in wild-type sequence and amplified nonspecific band in M001 ([Figure 2](#f2-tacg-11-001){ref-type="fig"}, lane labeled "WT+C"). As we know, M001 is a male patient with T mutant allelic *CHM* gene ([Figure 1B](#f1-tacg-11-001){ref-type="fig"}). The primer pair (WT2+C), with one base mismatch in wild-type sequence, amplified specific band only in normal person (M002) but not in patient (M001) ([Figure 2](#f2-tacg-11-001){ref-type="fig"}, lane labeled "WT2+C"). Both primer pairs (MT+C and MT2+C) amplified specific bands in the proband patient M001 with the mutant allele T ([Figure 2](#f2-tacg-11-001){ref-type="fig"}, lanes labeled "MT+C" and "MT2+C") but amplified nonspecific band in M002 ([Figure 2](#f2-tacg-11-001){ref-type="fig"}, lanes labeled "MT+C" and "MT2+C"), indicating that there is no difference between these two primer pairs. Thus, we optimized the ARMS condition by selecting primer pair (WT2+C) of wild-type and primer pair (MT+C) of mutant-type.

Evaluation of ARMS for gene diagnosis of CHM
--------------------------------------------

To complete the diagnosis of CHM, we used the primer pairs WT2+C and MT+C to amplify different DNA samples from all the family members and a normal male control (sample M051). As shown in [Figure 3A](#f3-tacg-11-001){ref-type="fig"}, the patient's DNA (M001) amplified the mutant allele but did not amplify the wild-type allele, which is consistent with our previous results (shown in [Figure 2](#f2-tacg-11-001){ref-type="fig"}); however, carrier daughter's DNA (M003) amplified both alleles. Sanger sequencing demonstrated that the daughter is heterozygous with one allele point mutation of *CHM* c.C799T ([Figure 3B](#f3-tacg-11-001){ref-type="fig"}). All the normal individuals' DNA (M002, M004, M050, including control M051) amplified only wild-type allele. Validation of the putative mutation was performed by Sanger sequencing ([Figure 3B](#f3-tacg-11-001){ref-type="fig"} and data not shown). The carrier M003 had a heterozygous variant from C→T and the mutant gene was same as her father, indicating that the mutant *CHM* gene is inherited from her father ([Figure 1B](#f1-tacg-11-001){ref-type="fig"} and [3B](#f3-tacg-11-001){ref-type="fig"}).

Evaluation of ARMS for quick and accurate prenatal gene diagnosis of CHM
------------------------------------------------------------------------

In this pedigree, M151 was the fetal baby of the carrier M003, and we amplified genetic material of M151 from amniotic fluid DNA using the same primers (WT2+C and MT+C) as for other family members used above. To evaluate ARMS for quick and accurate prenatal gene diagnosis of CHM, ARMS-PCR was performed and results are shown in [Figure 4A](#f4-tacg-11-001){ref-type="fig"}, which indicates that the fetus (M151) amplified both mutant as well as the wild-type allele, similar to his/her mother (M003). Sanger sequencing result of M151 further revealed a heterozygous mutation from C→T ([Figure 4B](#f4-tacg-11-001){ref-type="fig"}), confirming our ARMS results. PCR for *SRY* gene demonstrated that there was no Y chromosome, indicating that M151 was a female fetus which was demonstrated after birth. Thus, ARMS was performed very quickly, and its results were found to be very reliable and accurate for *CHM* gene prenatal diagnosis.

Therefore, the female fetus M151 has the same genotype as her mother by inheriting the pathogenic mutant gene from her grandfather passing on to her mother and then to herself. With genetic counseling, the mother decided to give birth to the baby, showing no symptoms of CHM with more than 3 years' of follow-up information.

Discussion
==========

As a rare X-linked recessive inherited disorder, CHM causes chorioretinal dystrophy with typical clinical features such as progressive degeneration of the choriocapillaris, RPE, and photoreceptors.[@b2-tacg-11-001],[@b6-tacg-11-001],[@b21-tacg-11-001] Different kinds of variants/mutations have been identified in *CHM* gene,[@b6-tacg-11-001],[@b8-tacg-11-001],[@b9-tacg-11-001] and also some methods have been applied to detect these mutations.[@b4-tacg-11-001],[@b21-tacg-11-001] Gene therapy and retinal transplantation of CHM are considered possible treatments and are in clinical trials from last few years. Thirteen different human retinal gene therapy clinical trials have been performed. The majority of these studies used adeno-associated virus type 2 (AAV2) as the gene transfer vector.[@b22-tacg-11-001],[@b23-tacg-11-001] To date, the safety assessment of gene therapy mediated by AAV2 in CHM patients has been finished already.[@b21-tacg-11-001] Another clinical study demonstrated significant progress and suggests that AAV8 might be a candidate vector for *CHM* gene therapy.[@b24-tacg-11-001] Therefore, individuals affected with CHM might be cured in the near future. However, gene therapy has still a long way to go in order to become a reality. Thus, prenatal diagnosis is the current used strategy that can prevent genetic disorders.

Mutations in *CHM* gene are known to lead CHM.[@b25-tacg-11-001],[@b26-tacg-11-001] Li et al reported that at least 147 kinds of mutations have been identified in patients with CHM, containing 39 nonsense mutations, 2 missense mutations, 25 splicing mutations, 32 small deletions, 5 small indels, 9 small insertions, 1 gross insertions/duplication, 31 gross deletions, and 3 complex rearrangements, based on HGMD® Professional 2012.4. All the aforementioned kinds of mutations are loss of function mutations except two types.[@b8-tacg-11-001],[@b27-tacg-11-001] In another study, they found 6 mutations including 1 nonsense, 2 splicings, and 3 small deletions,[@b28-tacg-11-001] and all of them are loss of function mutations. Cai et al added two novel mutations to expand the spectrum of CHM-related mutations in two unrelated Chinese families.[@b29-tacg-11-001] Guo et al discovered one frameshift mutation in a Chinese family.[@b30-tacg-11-001] In our studies, the mutation was identified by NGS and noninvasive prenatal testing (NIPT) of *SRY* gene.[@b17-tacg-11-001]

ARMS is a very technique that can detect known mutations involving single base changes or small deletions, by using sequence-specific PCR primers. In this study, we successfully applied this technique to evaluate the value of prenatal gene diagnosis for CHM. To the best of our knowledge, this is the first report on gene and prenatal gene diagnosis of CHM by ARMS. [Figure 5](#f5-tacg-11-001){ref-type="fig"} shows the diagram of ARMS strategy for *CHM* gene diagnosis by introducing one base mismatch T→C at 3rd position from 3′ end of both normal and mutant primers in our study.

Previously, Fu et al and Moghadam et al successfully used ARMS to diagnose β-thalassemia prenatally in China and Iran, respectively;[@b18-tacg-11-001],[@b31-tacg-11-001] Chiu et al applied this method to quantify given mutant mtDNA heteroplasmies,[@b32-tacg-11-001] whereas Newton et al used ARMS for antenatal diagnosis of cystic fibrosis.[@b33-tacg-11-001] Recently, Yang et al performed rapid gene diagnosis for retinitis pigmentosa,[@b34-tacg-11-001] and Singh et al performed prenatal gene diagnosis for sickle cell disease by ARMS.[@b35-tacg-11-001] More recently, Aquino et al performed ARMS-PCR to detect the most common mutations of the *CFTR* gene in Peruvian patients with cystic fibrosis.[@b36-tacg-11-001] Shah et al combined ARMS and DNA sequencing to diagnose β-thalassemia in East-Western Indian population for better management.[@b37-tacg-11-001] From the above instances, it is noteworthy that ARMS can be used in the pre- and postnatal diagnosis of various genetic diseases.[@b38-tacg-11-001] Although there are many sophisticated tools applied to clinical diagnosis, it is very expensive for people in western China and some other undeveloped countries. As for known mutations in genes, ARMS provides an optional way to solve this problem with its additional characteristics such as time-efficient, unbiased, sensitive, accurate, rapid, and reliable. In our study, we successfully developed the ARMS technique by using wild-type or mutant-type primers with matched or one-base mismatched to examine the known mutation in the *CHM* gene. Furthermore, we tried to obtain samples to test how early ARMS method can be applied in clinical settings, and currently, we are isolating cff DNAs from different stages to test whether ARMS work.

Taken together, ARMS could be useful for quick and accurate prenatal gene diagnosis of CHM for *CHM* gene as well as other genetic diseases in undeveloped and developing countries which are in shortage of medical resources and supplies.
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![The pedigree of choroideremia and *CHM* gene mutation.\
**Notes: (A**) Pedigree of choroideremia. (**B**) The proband (I:1) with *CHM* nonsense variant (CHM:NM_000390:c.C799T:p.R267X) is indicated by an arrow as a filled square, exhibiting a 799 C→T mutation at the first nucleotide position of codon 267 (R267X) in the exon 6 of the *CHM* gene locus (cga-tga). (**C**) The proband's son (II:3) harbors normal DNA sequences. The carrier (II:2) is a female of proband's daughter and is pregnant with a fetus (III:2) who underwent prenatal diagnosis to demonstrate whether the baby inherited a normal X-chromosome. All of the Sanger sequencing results in this study used reverse complementary sequencing of the gene. The black arrow shows the position of the point mutation. The primer pair of CHM-L and CHM-R was used for PCR amplification and primer CHM-R for Sanger sequencing.](tacg-11-001Fig1){#f1-tacg-11-001}

![Optimization of ARMS condition.\
**Notes:** ARMS amplifications specific for the mutation (c.C799T) were optimized by indicated different primer pairs. The genomic samples of mutant hemizygous proband M001 (I:1) and his normal son (II:3) were used as DNA templates. The black and blue arrows show the position of the point mutation and nonspecific primer-dimer, respectively. I:1=M001; II:3=M002.\
**Abbreviations:** ARMS, amplification refractory mutation system; WT, wild-type primer; MT, mutant primer; C, common primer.](tacg-11-001Fig2){#f2-tacg-11-001}

![ARMS amplification by primers CHM-WT2 (WT2) and CHM-Common, and primers CHM-MT and CHM-Common.\
**Notes:** (**A**) ARMS amplification for different DNA samples. The black arrow shows the specific PCR products. (**B**) Verification of M003 by Sanger sequencing. The black arrow shows the position of the point mutation. I:1=M001; II:3=M002; II:2=M003; III:1=M004; II:1=M050; M051=Normal male control.\
**Abbreviations:** ARMS, amplification refractory mutation system; CHM, choroideremia; WT, wild-type primer; MT, mutant primer; C, common primer.](tacg-11-001Fig3){#f3-tacg-11-001}

![ARMS amplification from fetal amniotic fluid DNA (III:2) by primers CHM-WT2 (WT2) and Common primer CHM-C3, and primers CHM-MT and CHM-Common.\
**Notes:** (**A**) ARMS amplification. The black and blue arrows show the position of the point mutation of the specific PCR products and nonspecific primer-dimer, respectively. (**B**) Verification of M151 (III:2) by Sanger sequencing. The black arrow shows the position of point mutation. A heterozygous mutation with the (c.C799T:p.R267X) variant was identified (A) and confirmed (B). III:2=M151.\
**Abbreviations:** ARMS, amplification refractory mutation system; CHM, choroideremia; WT, wild-type primer; MT, mutant primer; C, common primer.](tacg-11-001Fig4){#f4-tacg-11-001}

![A diagram for ARMS strategy to diagnose *CHM* gene.\
**Notes:** (**A**) The normal and mutant target DNA sequences of *CHM* gene (black and blue solid lines) and the normal and mutant primers are depicted. One base mismatch T→C was introduced artificially at 3rd position (blue with underline) from 3′ end of both normal and mutant primers in our study. (**B**) Representative PCR products obtained by ARMS are interpreted from an agarose gel. Lane 1 presents the results from a normal individual using the ARMS primer with the normal or wild-type sequence, resulting in the target DNA product (solid line). Lane 2 also presents the results from a normal individual, but the ARMS primer now corresponds to the mutant sequence; thus, PCR amplification does not occur (dotted line). Lanes 3 and 4 reveal the results with a heterozygous individual, carrier. In lane 3, the ARMS primer corresponds to wild-type sequence with PCR amplification of target DNA (from one allele C) (solid line) and in lane 4, the ARMS primer corresponds to mutant sequence with PCR amplification of target DNA (from the other allele T) (solid line). Lanes 5 and 6 reveal the results from a male patient with the mutation on an allele T in X chromosome gene *CHM* (hemizygote). Lane 5 represents the results with an ARMS primer that corresponds to wild-type sequence with no PCR amplification (dotted line); lane 6 uses an ARMS primer that corresponds to the mutant sequence, with amplification of target DNA (solid line). The black arrow points to the specific PCR products.\
**Abbreviations:** ARMS, amplification refractory mutation system; CHM, choroideremia.](tacg-11-001Fig5){#f5-tacg-11-001}

###### 

Amplification refractory mutation system and their combination

  Primer combination   5′-specific primer   Sequence (5′-3′)                       3′-common primer   Sequence (5′-3′)        Size (bp)
  -------------------- -------------------- -------------------------------------- ------------------ ----------------------- -----------
  WT+C                 CHM-WT               ATTACCAGGATTCTTGCATTTC                 CHM-C3             GCTCTGCTCTTCTGGAAGCTG   490
  MT+C                 CHM-MT               ATTACCAGGATTCTTGCATTT[T]{.ul}          CHM-C3             GCTCTGCTCTTCTGGAAGCTG   490
  WT2+C                CHM-WT2              ATTACCAGGATTCTTGCAT[C]{.ul}TC          CHM-C3             GCTCTGCTCTTCTGGAAGCTG   490
  MT2+C                CHM-MT2              ATTACCAGGATTCTTGCAT[C]{.ul}T[T]{.ul}   CHM-C3             GCTCTGCTCTTCTGGAAGCTG   490

**Abbreviations:** WT, wild-type primer; MT, mutant primer; C, common primer; CHM, choroideremia.

###### 

Sequences of PCR primers and PCR product size (bp)

  Name   5′-primer   Sequence (5′-3′)        3′-primer   Sequence (5′-3′)       Size   Tm (°C)
  ------ ----------- ----------------------- ----------- ---------------------- ------ ---------
  CHM    CHM-L       TGGGAGAAAAGGATTTGTGTG   CHM-R       ATGGATCAGGTTTTGCTGCT   637    60

**Note:** CHM-L was used for Sanger sequencing.

**Abbreviations:** L, left; R, right; bp, base pair; CHM, choroideremia.
